Galena acquires US rights to Orexo Abstral sublingual tablets
The FDA approved sublingual tablets are indicated for the management of breakthrough cancer pain (BTcP) in opioid tolerant patients. According to the terms of the deal, Orexo will
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.